Astrana Health, Inc. (NASDAQ:ASTH) Short Interest Update

Astrana Health, Inc. (NASDAQ:ASTH) saw a significant decline in short interest during the month of December. As of December 31st, there was short interest totalling 1,490,000 shares, a decline of 8.6% from the December 15th total of 1,630,000 shares. Currently, 4.2% of the shares of the stock are sold short. Based on an average trading volume of 303,600 shares, the days-to-cover ratio is presently 4.9 days.

Hedge Funds Weigh In On Astrana Health

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Central Pacific Bank Trust Division purchased a new stake in shares of Astrana Health during the third quarter worth about $160,000. SG Americas Securities LLC purchased a new stake in Astrana Health during the 3rd quarter worth approximately $680,000. Granite Bay Wealth Management LLC acquired a new position in shares of Astrana Health in the 3rd quarter valued at approximately $290,000. Handelsbanken Fonder AB purchased a new position in shares of Astrana Health during the 3rd quarter valued at approximately $492,000. Finally, GAMMA Investing LLC acquired a new stake in shares of Astrana Health during the third quarter worth approximately $34,000. Hedge funds and other institutional investors own 52.77% of the company’s stock.

Astrana Health Stock Up 5.4 %

ASTH opened at $35.17 on Monday. The company has a market cap of $1.98 billion, a PE ratio of 27.05, a price-to-earnings-growth ratio of 1.12 and a beta of 1.20. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.91 and a current ratio of 1.91. Astrana Health has a 1 year low of $29.08 and a 1 year high of $63.20. The firm has a 50 day moving average price of $37.26 and a 200 day moving average price of $46.77.

Astrana Health (NASDAQ:ASTH) last posted its earnings results on Thursday, November 7th. The company reported $0.33 earnings per share for the quarter, meeting the consensus estimate of $0.33. The business had revenue of $478.71 million for the quarter, compared to analyst estimates of $462.01 million. Astrana Health had a net margin of 3.63% and a return on equity of 9.37%. During the same quarter in the previous year, the business posted $0.47 EPS. Sell-side analysts expect that Astrana Health will post 1.16 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently commented on the company. Macquarie raised Astrana Health to a “hold” rating in a research note on Monday, December 16th. KeyCorp assumed coverage on shares of Astrana Health in a research report on Friday, October 11th. They issued a “sector weight” rating for the company. TD Cowen started coverage on shares of Astrana Health in a research report on Monday, October 14th. They set a “buy” rating and a $66.00 target price on the stock. BTIG Research increased their price target on Astrana Health from $60.00 to $70.00 and gave the stock a “buy” rating in a research note on Thursday, October 3rd. Finally, Robert W. Baird lifted their price objective on Astrana Health from $67.00 to $86.00 and gave the company an “outperform” rating in a research report on Wednesday, November 13th. Two research analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $63.67.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.